JUNIPER-NETWORKS
15.3.2022 13:49:04 CET | Business Wire | Press release
Juniper Networks , (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Raiffeisen Informatik (R-IT), a provider of comprehensive IT-services for financial service and insurance providers, has deployed Juniper Apstra data center solutions to modernize and automate its network infrastructure to provide exceptional services for its customers.
R-IT works consistently and emphatically to provide high-quality services and fail-safe infrastructures to its customers 24/7. R-IT’s long standing customers rely on the provider’s consistent and innovative solutions that significantly increase their flexibility as well as R-IT’s added value, from lending business and receivables management through securities settlement, to data management and digitalized accounting.
Juniper Apstra, the company’s data center solution for automation, will simplify planning, design and operations for R-IT’s network teams, reducing configuration errors for a more predictable data center network while maximizing both reliability and speed to create a better user experience.
News Highlights:
- R-IT can simplify and automate its operations from design to deployment (Day 0 and 1) through everyday operations and assurance with the turnkey Apstra System.
- Apstra usesroot-cause analysis to reduce the duration of network issues and shorten maintenance time with maintenance-mode capabilities. With Apstra, R-IT can dramatically reduce the time needed to deliver new network services, achieving faster time to deployment and time to resolution.
- With automated, flexible and simplified operations, R-IT can push out new application updates and services with minimal downtime for smooth, consistent user experiences.
- By automating the network lifecycle, IT resources can be used more efficiently, freeing up the company’s talented IT staff for strategic work. Pressure on hiring infrastructure and operations staff is expected to be relieved.
- With its open, flexible architecture, Apstra enables R-IT to deploy and operate multivendor networks with the ease and simplicity of a single-vendor network.
- In R-IT’s data centers, Juniper QFX Series Switches provide a flexible network fabric with industry-leading throughput and scalability, an extensive routing stack, the open programmability of the Junos® OS and a broad set of EVPN-VXLAN and IP fabric capabilities.
Supporting quotes:
“Our deep industry knowledge and strong foundation help ensure that our customers receive the best IT service at the highest levels of security, performance and availability, so they can concentrate on their core processes. Juniper Apstra provides an automated network platform that allows us to serve our customers with greater business agility.”
- Michael Linhart, CEO, Raiffeisen Informatik
“Financial institutions are looking for operational services that are reliable, resilient and agile. R-IT is providing critical services to its customers 24/7, and Juniper supports that with our objective to fully automate changes and assure continuous operation. With intent-based networking automation to help modernize and automate R-IT’s complete data center, Apstra increased reliability without more headcounts.”
- Mike Bushong, Vice President, Data Center Product Management, Juniper Networks
Additional resources:
- Success Story: R-IT
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005126/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom